Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

Sazan Rasul; Markus Hartenbach; Tim Wollenweber; Elisabeth Kretschmer-Chott; Bernhard Grubmüller; Gero Kramer; Shahrokh Shariat; Wolfgang Wadsak; Markus Mitterhauser; Verena Pichler; Chrysoula Vraka; Marcus Hacker; Alexander R Haug

doi:10.1007/s00259-020-05082-5

Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

Sazan Rasul, Markus Hartenbach, Tim Wollenweber, Elisabeth Kretschmer-Chott, Bernhard Grubmüller, Gero Kramer, Shahrokh Shariat, Wolfgang Wadsak, Markus Mitterhauser, Verena Pichler, Chrysoula Vraka, Marcus Hacker, Alexander R Haug (Corresponding author)

Publications: Contribution to journal › Article › Peer Reviewed

Original language	English
Pages (from-to)	1650–1657
Number of pages	8
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	48
Issue number	5
Early online date	2020
DOIs	https://doi.org/10.1007/s00259-020-05082-5
Publication status	Published - May 2021
Externally published	Yes

Austrian Fields of Science 2012

302054 Nuclear medicine

Keywords

mCRPC
PSA
PSMA-RLT
Response prediction
Survival prediction
PSMA
RADIOLIGAND THERAPY
CHEMOTHERAPY
ANTIGEN

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00259-020-05082-5Licence: CC BY 4.0

Cite this

Rasul, S., Hartenbach, M., Wollenweber, T., Kretschmer-Chott, E., Grubmüller, B., Kramer, G., Shariat, S., Wadsak, W., Mitterhauser, M., Pichler, V., Vraka, C., Hacker, M., & Haug, A. R. (2021). Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48(5), 1650–1657. https://doi.org/10.1007/s00259-020-05082-5

@article{9394e88810f44d5984f43dd8965efc96,

title = "Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer",

keywords = "mCRPC, PSA, PSMA-RLT, Response prediction, Survival prediction, PSMA, RADIOLIGAND THERAPY, CHEMOTHERAPY, ANTIGEN",

author = "Sazan Rasul and Markus Hartenbach and Tim Wollenweber and Elisabeth Kretschmer-Chott and Bernhard Grubm{\"u}ller and Gero Kramer and Shahrokh Shariat and Wolfgang Wadsak and Markus Mitterhauser and Verena Pichler and Chrysoula Vraka and Marcus Hacker and Haug, {Alexander R}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2021",

month = may,

doi = "10.1007/s00259-020-05082-5",

language = "English",

volume = "48",

pages = "1650–1657",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "5",

}

Rasul, S, Hartenbach, M, Wollenweber, T, Kretschmer-Chott, E, Grubmüller, B, Kramer, G, Shariat, S, Wadsak, W, Mitterhauser, M , Pichler, V, Vraka, C, Hacker, M & Haug, AR 2021, 'Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 5, pp. 1650–1657. https://doi.org/10.1007/s00259-020-05082-5

Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. / Rasul, Sazan; Hartenbach, Markus; Wollenweber, Tim et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, No. 5, 05.2021, p. 1650–1657.

Publications: Contribution to journal › Article › Peer Reviewed

TY - JOUR

T1 - Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

AU - Rasul, Sazan

AU - Hartenbach, Markus

AU - Wollenweber, Tim

AU - Kretschmer-Chott, Elisabeth

AU - Grubmüller, Bernhard

AU - Kramer, Gero

AU - Shariat, Shahrokh

AU - Wadsak, Wolfgang

AU - Mitterhauser, Markus

AU - Pichler, Verena

AU - Vraka, Chrysoula

AU - Hacker, Marcus

AU - Haug, Alexander R

PY - 2021/5

Y1 - 2021/5

KW - mCRPC

KW - PSA

KW - PSMA-RLT

KW - Response prediction

KW - Survival prediction

KW - PSMA

KW - RADIOLIGAND THERAPY

KW - CHEMOTHERAPY

KW - ANTIGEN

UR - http://www.scopus.com/inward/record.url?scp=85094655393&partnerID=8YFLogxK

U2 - 10.1007/s00259-020-05082-5

DO - 10.1007/s00259-020-05082-5

M3 - Article

C2 - 33128131

SN - 1619-7070

VL - 48

SP - 1650

EP - 1657

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 5

ER -

Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G et al. Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2021 May;48(5):1650–1657. Epub 2020. doi: 10.1007/s00259-020-05082-5

Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer